Study on prevalence and molecular mechanisms of antibacterial resistance in gramnegative pathogens of nosocomial infections in hospitals of Moscow and Perm

Antibiotiki i Khimioterapiya

Volumn 52, Issue 7-8, 2007, Pages 10-16

  Mudrak, D E ^a,b   Ikryannikova, L N ^a,b   Sidorenko, S V ^a,b   Ilyina, E N ^a,b  

^a National Research Centre of Antibiotics   (Russian Federation)

^b FEDERAL RESEARCH AND CLINICAL CENTER OF PHYSICAL CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY   (Russian Federation)

Author keywords

Antibacterial resistance; Gramnegative organisms; Nosocomial infections

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CROSS INFECTION; DRUG EFFECT; ENTEROBACTERIACEAE; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; GRAM NEGATIVE BACTERIUM; HUMAN; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; RUSSIAN FEDERATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CROSS INFECTION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MOSCOW; PSEUDOMONAS AERUGINOSA; RUSSIA;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; ESCHERICHIA COLI;

EID: 48249142900     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sturenburg E., Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003; 47: 4: 273-295.
2. Gniadkowski M. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001; 7: 11: 597-608.
3. Giamarellou H. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2005; 11: Suppl 4: 1-16.
4. Nathisuwan S., Burgess D. S., Lewis J. S. 2nd. Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001; 21: 8: 920-928.
5. Sekowska A. et al. Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics. Med Sci Monit 2002; 8: 3: BR100-104.
6. Spanu T. et al. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46: 1: 196-202.
7. Bradford P. A. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 4: 933-51. table of contents.
8. Institute C.A.L.S. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Clinical and Laboratory Standards Institution. Wayne, Pa, 2007.
9. Russian source
10. Institute C.A.L.S., Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard - seventh edition. Clinical and Laboratory Standards Institution. Wayne. Pa 2007.
11. Ellington M. J. et al. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J Antimicrob Chemother 2007; 59: 2: 321-322.
12. Page M. G. Extended-spectrum beta-lactamases: structure and kinetic mechanism. Clin Microbiol Infect 2008; 14: s1: 63-74.
13. Egorova S. et al. Prevalence and characterization of extended-spectrum cephalosporin-resistant nontyphoidal Salmonella isolates in adults in Saint Petersburg, Russia (2002-2005). Microb Drug Resist 2007; 13: 2: 102-107.
14. Edelstein M. et al. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother 2003; 47: 12: 3724-3732.
15. Domnikova N. P. et al. Isolation rate of gram negative microflora and its sensitivity to antibiotics in hemoblastosis patients. Zh Mikrobiol Epidemiol Immunobiol 2004; 3: 3-6.
16. Canton R. et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Emerobacteriaceae in Europe. Clin Microbiol Infect 2008; 14: s1: 144-153.
17. Livermore D. M., Woodford N. The beta-lactamase threat in Enterobacteriaceae. Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 9: 413-420.
18. Villegas M. V. et al. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect 2008; 14: s1: 154-158.
19. Bush K. Extended-spectrum beta-lactamases in North America. 1987-2006. Clin Microbiol Infect 2008; 14: s1: 134-143.
20. Hawkey P. M. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008: 14: s1: 159-165.
21. Kumar A., Schweizer H. P. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 2005; 57: 10: 1486-513.
22. Queenan A. M., Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20: 3: 440-458. table of contents.